Phase II | sciencenewsnet.in

Breaking News

Technological Breakthrough in Carbon Nanotube Applications for Battery Dry Process

Lack of control at work identified as cause for physician burnout and attrition

Expanding HPV vaccination to all adults aged 27-45 years unlikely to be cost-effective or efficient for HPV-related cancer prevention

University Student’s Start-Up Expands, Connecting Small Coffee Farmers to the World

FSU physicists will study nuclear reactions of stars with support from National Science Foundation

Warning: don’t miss Thanksgiving dinner, it’s more meaningful than you think

Roswell Park Launches First-of-Its-Kind Oncology Training Program for Nurse-Scientists With $2M NCI Grant

UT Southwestern brings first-of-its-kind radiation oncology to new $177M campus in Fort Worth Medical District

Tips and recipes for a healthy holiday season from a doctor and a dietitian

X-ray Measurements Reveal an Unexpected Role for Copper in Photocatalysts

26 Nov, 2024

New medication for stress urinary incontinence? Investigational drug shows promise

July 11, 2024 sarah JonasResearch Results

An investigational medication designated TAS-303 shows efficacy and safety in treatment of women with stress urinary incontinence (SUI), reports a placebo-controlled clinical trial in the August issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Dual immunotherapy plus chemotherapy before surgery improves patient outcomes in operable lung cancer

March 16, 2023 sarah JonasResearch Results

In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).